信立泰(002294.SZ):股東潤復擬將所持0.45%股份無償捐贈給北京市中國人民大學教育基金會
格隆匯1月15日丨信立泰(002294.SZ)公佈,公司近日收到股東深圳市潤復投資發展有限公司的通知,為支持中國人民大學的人才培養、教學科研等教育事業發展,其計劃將所持有的無限售條件流通股500萬股(佔公司總股本比例0.45%),以非交易過户的方式無償捐贈給北京市中國人民大學教育基金會,主要用於學校的全球發展與安全高等研究院的籌建和運行。
截至本公吿披露日,潤復持有公司股份22,465,952股,佔公司總股本比例2.02%;捐贈完成後,潤復將持有公司股份17,465,952股,佔公司總股本比例1.57%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.